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Objective: Accounting for patient preferences may be especially important in diabetes   mellitus, 
given the challenge in identifying factors associated with treatment adherence. Although 
  preference studies have been performed in diabetes, none have examined treatments used 
in diabetic retinopathy (DR). The objective of this study was to elicit patient preferences for 
attributes associated with antivascular endothelial growth factor, focal and panretinal laser, and 
steroid therapy used in DR management.
Methods: A cross-sectional conjoint survey was administered to DR patients at three   Canadian 
eye centers. The survey involved making tradeoffs among 11 DR treatment attributes, includ-
ing the chance of improving vision and risks of adverse events over a 1-year treatment period. 
Attribute utilities were summed for each product profile to determine the most preferred 
treatment.
Results: Based on the results from 161 patients, attributes affecting visual functioning, 
  including improving visual acuity and reducing adverse events (eg, chance of cataracts), were 
more important than those not directly affecting vision (eg, administration). Overall, 52%, 20%, 
17%, and 11% preferred the product profiles matching to the antivascular endothelial growth 
factor, steroid, focal laser, and panretinal laser therapies. Preferences did not vary substantially 
by previous treatment experience, age, or type of DR (macular edema, proliferative DR, both 
or neither), with the exception that more macular edema only patients preferred focal laser over 
steroid treatment (19% versus 14%, respectively).
Conclusions: When considering the potential effects of treatment over a 1-year period, treat-
ment preferences in DR are most influenced by those that may positively or negatively affect 
visual functioning.
Keywords: diabetes, retinopathy, patient preference, ophthalmology, conjoint analysis
Introduction
An underlying theme of the American Diabetes Association treatment guidelines is 
that providers should elicit and incorporate patient preferences in treatment decisions.1 
Individualizing patient care and accounting for patient preferences may be especially 
important in diabetes mellitus, given the challenge in identifying key factors associated 
with adherence to recommended chronic care and more favorable clinical outcomes 
over the long term.2 In addition, as Brown et al have observed, preferences among 
older diabetes patients for intensity of treatment regimen vary widely and are not 
closely associated with clinical status, eg, life expectancy and amount of functional 
decline.1 Although adherence to recommended care can markedly reduce   complication 
rates in diabetes mellitus, it has been estimated that 45% of persons diagnosed with 
diabetes mellitus in the US actually adhere to such care.3 A better understanding of Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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patient preferences with respect to treatment may help to 
inform adherence rates, as suggested by previous studies 
in diabetes.4,5
Thus far, treatment preferences in diabetes have focused 
predominantly on treatment for glucose   control and 
  perceptions regarding treatment side effects.1,6,7 For example, 
Matza et al showed that side effects, such as weight gain 
or gastrointestinal adverse events, may impact patient 
  preferences in type 2 diabetes.6 Consistent with previous 
findings that increasing the complexity of glucose   therapies 
is associated with lower quality-of-life scores, Huang et al 
found that preferences for various glucose control regi-
mens vary substantially and may significantly impact the 
  cost-effectiveness of intensive glucose control among older 
patients with new-onset diabetes.7
Although treatment preference studies have been per-
formed focusing on glucose control, they are lacking for 
treatments that may be considered for patients with diabetic 
retinopathy. Diabetic retinopathy (DR), a common ophthal-
mic complication of diabetes, occurs in over 50% of diabetic 
patients. The manifestations of DR, diabetic macular edema, 
and proliferative diabetic retinopathy, can lead to vision 
loss, as well as legal blindness.8–10 A recent projection study, 
using data from the National Health Interview Survey and 
the US Consensus Bureau, estimated that the prevalence of 
DR among diabetes patients aged 40 years and older will 
increase threefold, reaching 16 million, by 2050.11 In Canada, 
  diabetes and DR have become a major public health problem, 
with nearly 5% of the population having diabetes, and 400 
of these patients developing blindness every year from their 
disease.12
Current treatment options for DR include laser photoco-
agulation, intravitreal steroid therapy, and, more recently, 
antiangiogenic intravitreal injections. Laser therapies, focal 
and panretinal argon photocoagulation laser, are the main-
stay of treatment but often do not lead to marked visual 
improvement.13–18 They also risk damaging the neurosensory 
retina, depending on the location and intensity of the laser 
application and through possible laser scar expansion.19,20 
Similarly long-term use of repeated intravitreal steroids to 
treat DR-related vision loss is limited due to the associated 
risk of elevated intraocular pressure and cataract formation.14 
Recently, antiangiogenic therapies that target vascular 
endothelial growth factor (VEGF) have been promising in 
treating DR, especially diabetic macular edema, and are 
being considered as a viable alternative and/or addition to 
laser and steroid therapies.16,18,21 However, because these 
anti-VEGF drugs have a relatively short half-life, they 
require frequent intravitreal injections. They may also carry 
an increased risk of cardiovascular events, such as heart 
attack and stroke, because of the role anti-VEGF plays 
systemically.16,21,22
Given that current DR treatments have advantages or disad-
vantages relative to each other, it would be useful to understand 
patient preferences associated with the different treatment-
  related features and clinical outcomes. Conjoint analysis, a 
methodology widely used in market research as well as in 
medical research studies, involves having respondents make 
tradeoffs among these features (attributes), such as mode of 
administration and risk of adverse events.23–25 The resulting data, 
or utilities, enable the assessment of the relative importance of 
each treatment attribute; specifically, they show the influence 
that each attribute has on overall treatment preferences. In the 
context of eye disease, the conjoint approach has been used 
to assess which factors in the management and treatment of 
glaucoma were of most importance to patients.26
The goal of the present study was to use conjoint analysis 
to elicit preferences for attributes associated with DR treat-
ments. Specifically, the survey aimed to assess the tradeoffs 
that DR patients in Canada are willing to make among attri-
butes associated with anti-VEGF, steroid, focal laser, and 
panretinal laser treatment. Although steroids and anti-VEGF 
treatment are currently offlabel treatment for diabetic macular 
edema, and panretinal laser is only used for proliferative 
diabetic retinopathy, all four treatments that may be used at 
some point for the diabetes patient with DR were included 
in this assessment for comprehensiveness.
Research design and methods
A total of 171 study participants were recruited from three 
Canadian clinical eye care centers for this cross-sectional 
study. The study followed the tenets of the Declaration of 
Helsinki, and the study protocol was approved by each 
site-specific Institutional Review Board. All participants 
had a medical diagnosis of DR, and all stages of the   disease 
were represented, including patients who had devel-
oped proliferative diabetic retinopathy, diabetic macular 
edema, both proliferative diabetic retinopathy and diabetic 
macular edema, and those with earlier-stage DR who had 
neither proliferative diabetic retinopathy nor diabetic 
  macular edema. All   participants were at least 18 years of 
age,   provided informed consent, and were compensated 
$50.00 for participation. Participants completed the conjoint 
survey via wide-screen computer monitors at the clinical 
sites. The survey was self-administered, and participants 
moved through the survey at their own pace, although Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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a research assistant was available at each site to answer 
questions as needed.
survey design
The 11 treatment attributes assessed in the survey were 
selected based on a literature review and consultation with 
three DR specialists. These attributes included mode of 
administration, required number of office visits, treatment-
related pain, the chance of improving central vision, and 
the risk of adverse events, such as cataracts, glaucoma, and 
cardiovascular events. The descriptions of these attributes 
were based on a time horizon of one year after beginning 
treatment. Based on the literature and expert input, base 
case estimates were identified for the attributes for each 
of the four target treatments, ie, anti-VEGF, steroid, focal 
laser, and panretinal laser treatment17,27–33 (Table 1). It should 
be noted that we did not include “cost of treatment” as an 
attribute because this is not an important driver or barrier to 
treatment in Canada.
From the clinical averages and ranges observed in our 
preliminary research, each attribute was described using 
2–3 levels that represented the full range of possibilities 
across the four DR treatments. These levels were not always 
the same estimates as in the base case scenario, but since the 
Table 1 Base case estimates for diabetic retinopathy treatments
Attribute Selective VEGF inhibitor Focal laser Panretinal laser  Steroid
number of physician visits  
to receive treatment over  
a one-year perioda
9 visits 2 visits 6 visits 2 visits
Administration of eye  
treatment
One injection of  
medicine into eye
Laser procedure, in 
which 40–60 spots are 
placed on a small area 
of the central retina
Laser procedure, in 
which approximately 
500 spots are placed 
across the retina
One injection of 
medicine into eye
Treatment-related pain  Mild pain at the time  
of treatment
Mild pain at the time 
of treatment
Moderate pain at the time of  
treatment, and some pain after  
treatment lasting for a day 
Mild pain at the 
time of treatment 
Benefit observed from 
subsequent treatmentsb
After treatment wears  
off, same benefit is  
observed with each  
subsequent treatment 
After treatment wears 
off, treatment benefit 
decreases with each 
subsequent treatment
After treatment wears off,  
treatment benefit decreases  
with each subsequent  
treatment
After treatment wears 
off, treatment benefit 
decreases with each 
subsequent treatment 
% chance of improving central  
vision, in which you can  
read two more lines of letters  
on a  vision chart 
30% 20% 33% 40%
% chance of having blurry  
or blank patches in central 
field of vision 
0% 20% 0% 0%
% chance of having blurry or 
blank patches in your side vision, 
which may result in difficulty 
noticing objects off to the side 
and seeing in dim light 
0% 0% 33% 0%
% chance of needing treatment 
daily drops for glaucoma, which 
is increased eye pressure
0% 0% 0% 35%
% chance of needing surgery  
for glaucoma (increased eye 
pressure) in an operating room
0% 0% 0% 2%
% chance of having misty vision 
and/or glare from lights because 
of cataract formation 
0% 0% 0% 40%
% chance of having heart  
attack or stroke which  
does not result in death
1% 0% 0% 0%
Note: aimprovement in central vision after repeated treatments; anumber of visits specifically to receive diabetic retinopathy treatment, not routine follow-ups or monitoring 
for side effects.
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base case estimates fell within the range of level values, they 
could be evaluated through interpolation. The levels were 
described using lay terminology, and the risks of adverse 
events were presented as “% chance”. In addition, props 
were used to further illustrate some of the attributes. The 
survey was pilot-tested in a sample of five DR patients to 
ensure that the language and questions were clear and easy 
to understand. No significant changes were required.
The survey had four sections. In the first section, patients 
were asked to rate the desirability of each attribute level 
on a seven-point scale from “very bad” to “very good”. In 
  section two, the importance of the most favorable level ver-
sus the least favorable level was rated from “not important” 
to “extremely important”. Third, participants completed a 
series of pair-wise comparisons; each question presented two 
treatment profiles with three attribute levels, and participants 
indicated which profile they preferred on a seven-point scale 
from “strongly prefer A” to “strongly prefer B”. This section 
was adaptive, ie, the responses to each paired comparison are 
used to update each respondent’s utilities, and to select the 
next pairwise comparison shown.24 This approach to conjoint 
analysis is called adaptive conjoint analysis.24,34 In the fourth 
section, respondents provided information on demographics 
and treatment experience.
Analysis
Univariate analyses were performed using SAS software 
(version 9.1; to characterize demographic and clinical char-
acteristics. Responses to previous treatment experience were 
used to identify four subgroups, ie, experience with laser, 
experience with injection, experience with both laser and 
injection, and treatment-naïve. Utilities were generated for 
every level of each attribute. This was an iterative process in 
which the desirability ratings of each respondent were used to 
calculate an initial set of attribute level utilities. Next, these 
initial utilities were refined based on responses to the attribute 
importance questions, so that the range of utilities within each 
attribute was proportional to the stated importance. Finally, 
based on the responses to the paired comparison questions, 
ordinary least squares regression was used to calculate the 
final set of utilities for the attribute levels.35 The utilities 
were summed for different treatment profiles (based on the 
respective combinations of attribute levels) to determine 
which treatment would be preferred.
Relative importance, expressed as a percentage of each 
of the attributes in influencing treatment decisions, was 
calculated for each participant by dividing the range of each 
attribute (utility of highest level–utility of lowest level) by 
the sum of ranges of all attributes, and multiplying it by 
100. The   utilities also were incorporated into regression 
models that added random variability at both the attribute 
and product levels. Approximately 100,000 sampling 
  iterations were then performed, yielding predictions about 
the   percentages of patients who would choose a specific 
treatment profile over the others offered. Given the   utility 
estimates generated for each attribute level, sensitivity 
analyses were also conducted to estimate the percentages 
of patients likely to choose each treatment over the others, 
given a range of hypothetic simulation scenarios.
Results
A total of 171 patients completed the survey. Of these, 
161 (94%) were included in the final analytic dataset. 
Ten   participants were excluded due to two or more illogical 
answers for the desirability of attributes section (eg, choosing 
a 1% chance of heart attack/stroke as more desirable than a 
0% chance). The study population had a mean age of 61 years 
(standard deviation [SD] 13, range 26–89), 79% were 
  Caucasian, 44% were college educated, and 55% were males. 
The mean time (±SD) since DR diagnosis was 8.7 ± 8.5 years. 
Thirty-one percent had diabetic macular edema, 25% had 
proliferative diabetic retinopathy, 26% had both, and 18% 
had neither. Forty-nine percent (n = 79) were treated with 
laser only, 3% (n = 5) with injection (either steroid and/or 
anti-VEGF) only, 22% (n = 36) with both laser and injection, 
and 25% (n = 41) were treatment-naive. Overall, 57% and 
37% had scotomas (blurry or blank patches) in their central 
and side vision, respectively. Fifty-three percent had cata-
racts, and 37% had undergone cataract surgery.
The responses to the first survey section consistently 
showed higher ratings for the more favorable attribute 
levels and lower ratings for the less favorable levels. For the 
administration mode attribute, the mean desirability ratings 
overall for focal laser, injection, and panretinal laser modali-
ties were 4.63, 3.69, and 3.42, respectively (range 1–7, with 
higher more favorable). Within subgroups, the mean desir-
ability rating for injection was 3.17 among treatment-naïve 
patients, and was 4.97 among those who have experienced 
both laser and injection.
Table 2 reports the relative importance estimates for each 
attribute based on their respective utilities. They reflect the 
extent to which the difference in importance between the 
best and worst levels of each attribute drives the decision 
to choose a DR treatment. Among all 11 attributes, those 
directly related to visual functioning were valued most 
highly by patients. Specifically, these were “chance of Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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improving central vision” (efficacy) and the chance of side 
effects that would contribute to further visual loss, such as 
cataract formation. Thus changes in these attributes would 
make the most difference in the perceived utility of a DR 
treatment. The visual functioning attributes (ie, chance of 
cataract formation, improving vision, peripheral or para-
central scotomas) each accounted for 10.9% to 12.8% of the 
total relative importance. The attributes that least impacted 
preferences were treatment-related pain, number of office 
visits, and mode of administration. Patients were willing 
to endure a higher frequency of office visits or injection or 
greater treatment-related pain in exchange for greater effi-
cacy, increased long-term benefit, and reduced risk of visual 
side effects (cataracts or scotomas). The relative importance 
estimates did not change substantially within subgroups 
based on past treatment experience, age, or previous cataract 
experience, and thus have not been tabulated.
Table 3 reports the estimated percentages of patients 
  preferring each DR treatment given the utilities for the base 
case attribute levels. In the overall population, an estimated 
52% of patients would prefer anti-VEGF over the other 
  treatments. Steroid therapy would be the second most pre-
ferred (20%), followed by focal laser (17%) and panretinal 
laser (11%). The estimated percentages did not differ sub-
stantially across subpopulations based on past treatment 
experience. Table 4 reports the percentages preferring each 
treatment profile stratified by type of retinopathy. The esti-
mates are consistent with those observed for the subgroups 
  categorized by treatment experience (from most to least 
preferred, anti-VEGF, steroid, focal laser, panretinal laser), 
Table 2 Relative importance of attributes in influencing patient preferences
Attribute Most favorable level Least favorable level Relative importance 
(% ± SEM)a
chance of cataract 
formation
0% 54% 12.8 ± 0.03
chance of improving 
vision
55% 15% 12.3 ± 0.06
chance of blurry/blank 
patches, side
0% 47% 11.5 ± 0.03
chance of blurry/blank 
patches, central
0% 20% 10.9 ± 0.02
Benefit observed from 
subsequent treatments
After treatment wears off, same  
benefit is observed with  
each subsequent treatment
After treatment wears off,  
treatment benefit decreases  
with each subsequent treatment
  9.6 ± 0.03
chance of needing daily 
drops for glaucoma
0% 50%   9.6 ± 0.03
chance of cardiovascular event 0% 3%   9.3 ± 0.03
chance of needing 
surgery for glaucoma
0% 5%   8.6 ± 0.03
number of physician visits 1 visit 9 visits   6.1 ± 0.03
Treatment-related pain Mild pain at the time  
of treatment
Moderate pain at the time of  
treatment, and some pain after  
treatment lasting for a day
  5.5 ± 0.03
Mode of administration Laser procedure, in which  
40–60 spots are placed on  
a small area of the central retina
Laser procedure, in which approximately  
500 spots are placed across the retina
  3.8 ± 0.03
Note: aratio data (10% is twice as important than 5%). 
Abbreviation: seM standard error of the mean.
Table 3 estimated percentages of patients preferring each diabetic retinopathy treatment given utilities of base case attributes
DR  
treatment
Overall  
(n = 161)  
% (SEM)
Treatment-  
naïve (n = 41)  
% (SEM)
Laser experience 
(n = 79)  
% (SEM)
Injection  
experience (n = 5)  
% (SEM)
Experience with both 
therapies (n = 36)  
% (SEM)
Anti-VegF 52% (1.7) 49% (3.8) 51% (2.2) 56% (8.5) 57% (3.3)
steroid 20% (1.2) 21% (2.4) 18% (1.4) 15% (2.8) 26% (3.0)
Focal laser 17% (1.1) 19% (2.4) 19% (1.7) 16% (7.8) 10% (1.3)
Panretinal laser 11% (0.8) 11% (1.6) 12% (1.2) 13% (1.9) 7% (1.4)
Abbreviations: Dr, diabetic retinopathy; Vegr, vascular endothelial growth factor; seM, standard error of the mean.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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with the exception that more patients with diabetic macular 
edema preferred the focal laser over steroid treatment (19% 
versus 14%, respectively).
Table 5 reports the percentages preferring each DR treat-
ment, given improvements in base case attribute levels for 
steroid, focal laser, and panretinal laser treatment. A series 
of stepwise analyses were performed such that improvements 
to individual attributes were implemented until each of anti-
VEGF’s comparators was preferred over anti-VEGF. Steroid 
therapy was preferred over anti-VEGF after improvements 
were made to the “chance of cataract formation” and “  benefit 
with subsequent treatment”. Focal laser was preferred 
over anti-VEGF when improvements were made to risk of 
  central scotomas and “benefit with subsequent treatment”, 
and panretinal laser required improvements in “benefit with 
subsequent treatment” and risk of peripheral scotomas to be 
preferred over anti-VEGF.
Finally, a stepwise analysis of anti-VEGF involved 
modifications to make the attributes less favorable. Worsen-
ing the attributes “pain” (from “mild” to “moderate”) and 
“chance of improving central vision” (from 30% to 15%) 
resulted in a slight shift in preference to steroid treatment. 
Specifically, with these changes, 32%, 31%, 22%, and 16% 
preferred steroid, anti-VEGF, focal laser, and panretinal laser 
therapies, respectively.
Discussion
To our knowledge, this study was the first to assess patient 
treatment preferences in DR. The DR treatment attributes 
valued most highly by patients were those that are directly 
related to visual functioning, including efficacy of the treat-
ment and chance of adverse events that could contribute to 
further visual loss. Least important were those attributes 
that did not directly affect vision, such as treatment-related 
pain and mode of administration. These results emphasize 
the importance that patients place on visual functioning and 
the impact it has on their quality of life. For example, some 
patients may not be willing to accept a treatment with a 
  possibility of improved efficacy if it is coupled with a greater 
chance of adverse events that may ultimately negatively 
affect vision.
The findings of this study were consistent with those of 
Bhargava et al who performed a conjoint study to assess 
attributes associated with glaucoma treatment in that 
Table 4 estimated percentages of patients preferring each diabetic retinopathy treatment given utilities of base case attributes by 
diabetic macular edema/proliferative diabetic retinopathy status
DR  
treatment
Neither DME nor PDR (n = 29) 
% (SEM)
DME only (n = 50)  
% (SEM)
PDR only (n = 40)  
% (SEM)
Both DME and PDR (n = 42) 
% (SEM)
Anti-VegF 51% (3.6) 56% (2.8) 46% (3.7) 54% (3.1)
steroid 21% (2.4) 14% (1.3) 27% (2.9) 21% (1.9)
Focal laser 17% (2.9) 19% (2.1) 17% (2.5) 15% (1.8)
Panretinal laser 11% (1.7) 12% (1.3) 10% (1.8) 11% (1.6)
Abbreviations: VegF, vascular endothelial growth factor; DMe, diabetic macular edema; Dr, diabetic retinopathy; PDr, proliferative diabetic retinopathy; seM, standard 
error of the mean.
Table 5 sensitivity analyses: Percentages preferring each diabetic retinopathy treatment given improvements in base case attribute levels*
Attribute improvements  Preferring  
anti  -VEGF (%)
Preferring  
steroid (%)
Preferring 
focal laser (%)
Preferring 
panretinal laser (%)
improvements to steroid treatment: 
  • cataracts (40% to 0%) 
  •   Benefit (benefit decreases to same 
benefit with subsequent treatment) 
 
25% 
 
59% 
 
9% 
 
7% 
improvements to focal laser: 
  •   Blurry/blank patches, central (20% to 0%)
 •    Benefit (benefit decreases to same 
benefit with subsequent treatment) 
 
31% 
 
12% 
 
51% 
 
6% 
improvements to panretinal laser: 
  •   Benefit (benefit decreases to same 
benefit with subsequent treatment)
  •   Blurry/blank patches, peripheral (33% to 0%)
 
35% 
 
14% 
 
10% 
 
41% 
Note: *Table presents all attributes that are needed to improve in order for the respective treatment to be more preferred than anti-VegF.
Abbreviation: VegF, vascular endothelial growth factor.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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the attributes substantially affecting visual functioning 
(side effects) ranked highest in relative importance and 
those related to treatment methods ranked lowest.26 Specifi-
cally, Bhargava’s findings showed that the most important 
treatment-related attributes for glaucoma were the risk of 
moderate visual loss (ie, the ability to continue to drive) and 
risk of long-term blindness. Least important included chance 
of surgical intervention and the use of topical medication. 
In our study of Canadian diabetic patients, the chances of 
cataract formation, improving vision, and pericentral or 
peripheral scotomas made the most difference in the per-
ceived utility of a DR treatment relative to other treatment 
attributes. In addition, our findings on importance were 
consistent with conclusions from conjoint studies in other 
medical disciplines. In a recent study of disease-modifying 
antirheumatic preferences, for example, the tradeoffs 
made by patients with rheumatoid arthritis suggested that 
adverse events (eg, nausea, diarrhea) from a therapy were 
a   significant driver of overall preference.34
The risk of cataract formation was a key driver in select-
ing a DR treatment, and the findings did not vary between 
those with versus those without cataract experience, or 
between those with versus those without cataract surgery 
experience. This finding indicates that, even though cata-
ract surgery is a relatively safe, quick, and predominantly 
painless procedure, patients still are willing to give up other 
favorable treatment attributes to avoid the risk of cataract 
development and surgery.
Our study co mpared the treatment preferences of patients 
who had never undergone DR therapy with those who had 
experienced injection (steroid or anti-VEGF), laser (focal or 
panretinal), or both. Preferences did not vary substantially 
between subgroups, suggesting that decisions are driven 
by the same factors (ie, those that relate directly to vision 
improvement or impairment) for all types of DR patients, 
regardless of treatment history. Even in patients who had 
experienced both laser and injection treatments, the prefer-
ence for anti-VEGF was strong, despite the disadvantage of 
anti-VEGF requiring frequent injections.
Our study had limitations. First, the treatment attribute 
descriptions were limited to what is expected over a one-year 
treatment period. Longer-term studies have shown that effi-
cacy, for example, is better for the focal laser versus steroid 
therapy over a 2-year period; thus, if we were to expand our 
time horizon, the results may differ significantly. Second, 
given that focal and panretinal lasers are the mainstay of DR 
treatment, and anti-VEGF and steroid are offlabel therapies, 
our sample included only five patients who had experience 
with injection but not laser therapy. In addition, our study 
was initiated before it was demonstrated in the literature 
that anti-VEGF carried a significant risk of endophthalmitis 
(intraocular inflammation, which can result in severe vision 
loss),36,37 and so this risk was not included as an attribute. 
It is possible that inclusion of endophthalmitis would have 
resulted in a weaker preference for anti-VEGF, although the 
sensitivity analyses showed that multiple modifications to 
the base case would be necessary to shift preferences away 
from this therapy.
Further limitations are that the participants in our sample 
did not represent the full range of patients with DR; the major-
ity were well educated (with at least some college education), 
and their vision loss was not so significant that they were 
unable to navigate through the survey. It is possible that 
patients with other sociodemographic and clinical character-
istics, particularly related to severity of visual impairment, 
would express preferences different from those expressed by 
our sample. In addition, a subset of our sample had never 
undergone laser or injection-based therapy, so we cannot be 
certain whether preferences for treatment of these patients 
would change after a treatment experience. Our analysis sug-
gests they would not. Further, all of the patients in our study 
were from Canada, where the socialized health care system 
prevents cost of treatment from being a driver or barrier to 
selecting treatment. In other industrialized nations, such as 
the US, treatment-related costs could present as an important 
factor determining patient preferences. Therefore, while our 
study has yielded important findings with implications for the 
medical community, future research is necessary to evaluate 
the generalizability of our conclusions.
Conclusion
In conclusion, this survey evaluated the tradeoffs that 
patients are willing to make among DR treatment attri-
butes and predicted treatment preferences under different 
medication scenarios. As may be expected, the most favored 
attributes were those associated with improving vision or 
preventing visual loss. Given that diabetes is increasing in 
prevalence globally, the volume of ophthalmic patients will 
also increase and require increased patient-physician part-
nership for better long-term DR management. The findings 
from this research may be useful in incorporating patients’ 
views into medical decision-making processes, patient 
education, cost resource allocations, and drug development. 
A better understanding of a patient’s preferences may help Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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to improve patient satisfaction and compliance with chronic 
DR management.
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